Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Antimicrob Agents Chemother
    August 2021
  1. PASCUA PNQ, Jones JC, Marathe BM, Seiler P, et al
    Baloxavir treatment delays influenza B virus transmission in ferrets and results in limited generation of drug-resistant variants.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0113721. doi: 10.1128/AAC.01137.
    >> Share

  2. GABORIT B, Dailly E, Vanhove B, Josien R, et al
    Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
    Antimicrob Agents Chemother. 2021;65:e0123721.
    >> Share

  3. LI R, Liclican A, Xu Y, Pitts J, et al
    Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells.
    Antimicrob Agents Chemother. 2021;65:e0060221.
    >> Share

  4. GAMMELTOFT KA, Zhou Y, Duarte Hernandez CR, Galli A, et al
    Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0268020.
    >> Share

    July 2021
  5. GOMIS-FONT MA, Pitart C, Del Barrio-Tofino E, Zboromyrska Y, et al
    Emergence of Resistance to Novel Cephalosporin-beta-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
    Antimicrob Agents Chemother. 2021;65:e0008921.
    >> Share

  6. LIMONTA D, Dyna-Dagman L, Branton W, Mancinelli V, et al
    Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65:e0049121.
    >> Share

  7. WU X, Li N, Wang G, Liu W, et al
    Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Antimicrob Agents Chemother. 2021;65:e0035021.
    >> Share

    June 2021
  8. MANTLO EK, Paessler S, Seregin A, Mitchell A, et al
    Luminore CopperTouch Surface Coating Effectively Inactivates SARS-CoV-2, Ebola Virus, and Marburg Virus In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0139020.
    >> Share

  9. RAMIREZ S, Fernandez-Antunez C, Galli A, Underwood A, et al
    Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Antimicrob Agents Chemother. 2021;65:e0009721.
    >> Share

    May 2021
  10. WANG L, Zhu Q, Xiang K, Zhang Y, et al
    Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

    March 2021
  11. MENGUAL-CHULIA B, Alonso-Cordero A, Cano L, Del Mar Mosquera M, et al
    Surveillance of Influenza A resistance to polymerase complex inhibitors by whole genome analysis, 2016-17, 2017-18 and 2018-19 Seasons, Eastern Spain.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.02718.
    >> Share

  12. YAN VC, Muller FL
    Remdesivir for COVID-19: Why Not Dose Higher?
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  13. DORGHAM K, Neumann AU, Decavele M, Luyt CE, et al
    Considering Personalized Interferon Beta Therapy for COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  14. JUNEJA K, Humeniuk R, Porter D, Cao H, et al
    Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?"
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  15. DAVOUDI-MONFARED E, Khalili H
    Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  16. GOOD SS, Westover J, Jung KH, Zhou XJ, et al
    AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  17. KUO CJ, Chao TL, Kao HC, Tsai YM, et al
    Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  18. MAY M, Chang M, Dietz D, Shoucri S, et al
    Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  19. TOMITA Y, Takeda M, Matsuyama S
    The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.00020.
    >> Share

    February 2021
  20. KORMAN TM
    Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  21. HOLLAND TL
    Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  22. TE VELTHUIS AJW, Zubkova TG, Shaw M, Mehle A, et al
    Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02605.
    >> Share

  23. MARTINEZ MA
    Plitidepsin: a repurposed drug for the treatment of COVID-19.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.00200.
    >> Share

    January 2021
  24. XU Y, Barauskas O, Kim C, Babusis D, et al
    Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  25. ACKLEY TW, McManus D, Topal JE, Cicali B, et al
    A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

    December 2020
  26. ALEISSA MM, Silverman EA, Paredes Acosta LM, Nutt CT, et al
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Antimicrob Agents Chemother. 2020;65.
    >> Share

  27. VANDERLINDEN E, Van Winkel N, Naesens L, Van Damme EJM, et al
    In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA and UDA as Inhibitors of Influenza a and B Virus Replication.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.01732.
    >> Share

    November 2020
  28. SUZUKI S, Nguyen CT, Ogata-Nakahara A, Shibata A, et al
    Efficacy of a cap-dependent endonuclease inhibitor and neuraminidase inhibitors against H7N9 highly pathogenic avian influenza virus causing severe viral pneumonia in cynomolgus macaques.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01825.
    >> Share

  29. MCCULLOUGH PA
    Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  30. YAN VC, Muller FL
    Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  31. LE MP, Le Beller C, Le Hingrat Q, Jaquet P, et al
    Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  32. DOI Y, Hibino M, Hase R, Yamamoto M, et al
    A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

    October 2020
  33. LE MP, Le Hingrat Q, Jaquet P, Wicky PH, et al
    Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  34. BUEHRLE DJ, Decker BK, Wagener MM, Adalja A, et al
    Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

    August 2020
  35. FERNANDEZ-CRUZ A, Ruiz-Antoran B, Munoz-Gomez A, Sancho-Lopez A, et al
    A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  36. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    >> Share

    July 2020
  37. GORDY JT, Mazumdar K, Dutta NK
    Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  38. DANION F, Ruch Y, Fourtage M, Kaeuffer C, et al
    The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  39. SALGADO-BENVINDO C, Thaler M, Tas A, Ogando NS, et al
    Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  40. DAVOUDI-MONFARED E, Rahmani H, Khalili H, Hajiabdolbaghi M, et al
    Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01061.
    >> Share

  41. MARZOLINI C, Stader F, Stoeckle M, Franzeck F, et al
    Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Antimicrob Agents Chemother. 2020 Jul 8. pii: AAC.01177.
    >> Share

  42. MARATHE BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, et al
    Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00284.
    >> Share

  43. MARTINEZ MA
    Clinical trials of repurposed antivirals for SARS-CoV-2.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.01101.
    >> Share

    June 2020
  44. SOFTIC L, Brillet R, Berry F, Ahnou N, et al
    Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  45. JEON S, Ko M, Lee J, Choi I, et al
    Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

    May 2020
  46. HOFFMANN M, Schroeder S, Kleine-Weber H, Muller MA, et al
    Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  47. LI H, Zhou Y, Zhang M, Wang H, et al
    Updated Approaches against SARS-CoV-2.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  48. LIM JJ, Nilsson AC, Silverman M, Assy N, et al
    A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00352.
    >> Share

  49. ADAMS SE, Lugovtsev VY, Kan A, Bovin NV, et al
    Laninamivir-Interferon-lambda1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly Than Laninamivir Alone.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00301.
    >> Share

    April 2020
  50. KOSHIMICHI H, Retout S, Cosson V, Duval V, et al
    Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00119.
    >> Share

  51. ZHAO L, Yan Y, Dai Q, Li X, et al
    Development of Novel Anti-influenza Thiazolides with Relatively Broad-spectrum Antiviral Potentials.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00222.
    >> Share

  52. NGUYEN CT, Suzuki S, Itoh Y, Ishigaki H, et al
    Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
    Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.02561.
    >> Share

    March 2020
  53. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    >> Share

    January 2020
  54. BROADBENT L, Parke HG, Ferguson LJ, Millar A, et al
    Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  55. DEVINCENZO J, Tait D, Efthimiou J, Mori J, et al
    A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

    September 2018
  56. FARRUKEE R, Zarebski AE, McCaw JM, Bloom JD, et al
    CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
    Antimicrob Agents Chemother. 2018 Sep 10. pii: AAC.01081.
    >> Share

    August 2018
  57. ALI SO, Takas T, Nyborg A, Shoemaker K, et al
    Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.00694.
    >> Share

    June 2018
  58. YOON JJ, Toots M, Lee S, Lee ME, et al
    Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00766.
    >> Share

    March 2018
  59. VIGIL A, Estelles A, Kauvar LM, Johnson SK, et al
    Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses.
    Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.02269.
    >> Share

    January 2018
  60. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".
    Antimicrob Agents Chemother. 2017;62.
    >> Share

  61. HUNSBERGER S, Memoli MJ
    Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.
    Antimicrob Agents Chemother. 2017;62.
    >> Share

    November 2017
  62. TSUJI BT, Fisher J, Boadi-Yeboah R, Holden PN, et al
    Azithromycin Pharmacodynamics against 'Persistent' Haemophilus influenza in Chronic Obstructive Pulmonary Disease.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.01995.
    >> Share

    August 2017
  63. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Challenge Model: A Phase 2 Randomized Trial.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01154.
    >> Share

    May 2017
  64. LIM JJ, Derby MA, Zhang Y, Deng R, et al
    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00279.
    >> Share

    April 2017
  65. STAROSILA D, Rybalko S, Varbanetz L, Ivanskaya N, et al
    Anti-influenza activity of Bacillus subtilis probiotic strain.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00539.
    >> Share

  66. GAILLARD V, Galloux M, Garcin D, Eleouet JF, et al
    A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
    Antimicrob Agents Chemother. 2017;61.
    >> Share

    March 2017
  67. GRIFFIN MP, Khan AA, Esser MT, Jensen K, et al
    Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Antimicrob Agents Chemother. 2017;61.
    >> Share

    February 2017
  68. JONES JC, Marathe BM, Vogel P, Gasser R, et al
    The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02460.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016